Last reviewed · How we verify

dexmedetomidine-esketamine-ropivacaine combination 1

Peking University First Hospital · FDA-approved active Small molecule

dexmedetomidine-esketamine-ropivacaine combination 1 is a Combination anesthetic/analgesic Small molecule drug developed by Peking University First Hospital. It is currently FDA-approved for Local/regional anesthesia with sedation and analgesia for procedures. Also known as: epidural analgesia using the dexmedetomidine-esketamine-ropivacaine combination 1.

This combination provides sedation and analgesia through alpha-2 adrenergic agonism (dexmedetomidine), dissociative anesthesia (esketamine), and local anesthetic blockade (ropivacaine).

This combination provides sedation and analgesia through alpha-2 adrenergic agonism (dexmedetomidine), dissociative anesthesia (esketamine), and local anesthetic blockade (ropivacaine). Used for Local/regional anesthesia with sedation and analgesia for procedures.

At a glance

Generic namedexmedetomidine-esketamine-ropivacaine combination 1
Also known asepidural analgesia using the dexmedetomidine-esketamine-ropivacaine combination 1
SponsorPeking University First Hospital
Drug classCombination anesthetic/analgesic
TargetAlpha-2 adrenergic receptor, NMDA receptor, voltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Dexmedetomidine acts as a selective alpha-2 adrenergic agonist producing sedation and analgesia. Esketamine is an NMDA receptor antagonist providing dissociative anesthesia and analgesia. Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers. Together, this combination provides multimodal anesthesia and analgesia for procedural use.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about dexmedetomidine-esketamine-ropivacaine combination 1

What is dexmedetomidine-esketamine-ropivacaine combination 1?

dexmedetomidine-esketamine-ropivacaine combination 1 is a Combination anesthetic/analgesic drug developed by Peking University First Hospital, indicated for Local/regional anesthesia with sedation and analgesia for procedures.

How does dexmedetomidine-esketamine-ropivacaine combination 1 work?

This combination provides sedation and analgesia through alpha-2 adrenergic agonism (dexmedetomidine), dissociative anesthesia (esketamine), and local anesthetic blockade (ropivacaine).

What is dexmedetomidine-esketamine-ropivacaine combination 1 used for?

dexmedetomidine-esketamine-ropivacaine combination 1 is indicated for Local/regional anesthesia with sedation and analgesia for procedures.

Who makes dexmedetomidine-esketamine-ropivacaine combination 1?

dexmedetomidine-esketamine-ropivacaine combination 1 is developed and marketed by Peking University First Hospital (see full Peking University First Hospital pipeline at /company/peking-university-first-hospital).

Is dexmedetomidine-esketamine-ropivacaine combination 1 also known as anything else?

dexmedetomidine-esketamine-ropivacaine combination 1 is also known as epidural analgesia using the dexmedetomidine-esketamine-ropivacaine combination 1.

What drug class is dexmedetomidine-esketamine-ropivacaine combination 1 in?

dexmedetomidine-esketamine-ropivacaine combination 1 belongs to the Combination anesthetic/analgesic class. See all Combination anesthetic/analgesic drugs at /class/combination-anesthetic-analgesic.

What development phase is dexmedetomidine-esketamine-ropivacaine combination 1 in?

dexmedetomidine-esketamine-ropivacaine combination 1 is FDA-approved (marketed).

What are the side effects of dexmedetomidine-esketamine-ropivacaine combination 1?

Common side effects of dexmedetomidine-esketamine-ropivacaine combination 1 include Hypotension, Bradycardia, Sedation, Dissociative effects, Local anesthetic toxicity.

What does dexmedetomidine-esketamine-ropivacaine combination 1 target?

dexmedetomidine-esketamine-ropivacaine combination 1 targets Alpha-2 adrenergic receptor, NMDA receptor, voltage-gated sodium channels and is a Combination anesthetic/analgesic.

Related